Total Payments
$218,647
2024 Payments
$67,776
Companies
19
Transactions
166
Medicare Patients
214
Medicare Billing
$74,248
Payment Breakdown by Category
Consulting$88,144 (40.3%)
Other$47,118 (21.5%)
Travel$40,114 (18.3%)
Royalty/License$40,000 (18.3%)
Food & Beverage$3,271 (1.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $88,144 | 34 | 40.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $47,118 | 9 | 21.5% |
| Travel and Lodging | $40,114 | 63 | 18.3% |
| Royalty or License | $40,000 | 1 | 18.3% |
| Food and Beverage | $3,271 | 59 | 1.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $53,227 | 54 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $44,893 | 5 | $0 (2024) |
| Otsuka Pharmaceutical Co., Ltd. | $26,265 | 28 | $0 (2023) |
| Amgen Inc. | $20,312 | 4 | $0 (2019) |
| Merck Sharp & Dohme LLC | $17,735 | 19 | $0 (2024) |
| Alkermes, Inc. | $10,683 | 9 | $0 (2021) |
| Janssen Pharmaceuticals, Inc | $9,288 | 16 | $0 (2019) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $8,832 | 7 | $0 (2023) |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $7,488 | 6 | $0 (2021) |
| Boehringer Ingelheim International GmbH | $6,608 | 4 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $67,776 | 63 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) ($53,227) |
| 2023 | $39,910 | 50 | Otsuka Pharmaceutical Co., Ltd. ($26,265) |
| 2022 | $8,526 | 6 | Boehringer Ingelheim International GmbH ($3,700) |
| 2021 | $7,061 | 7 | PFIZER INTERNATIONAL LLC ($4,500) |
| 2020 | $5,945 | 3 | SK Life Science, Inc. ($3,200) |
| 2019 | $37,878 | 26 | Amgen Inc. ($20,312) |
| 2018 | $11,376 | 9 | Alkermes, Inc. ($8,264) |
| 2017 | $40,175 | 2 | Otsuka America Pharmaceutical, Inc. ($40,000) |
All Payment Transactions
166 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,850.00 | General |
| Category: PSYCHIATRY | ||||||
| 12/11/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| 12/11/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: PSYCHIATRY | ||||||
| 12/11/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Travel and Lodging | Cash or cash equivalent | $45.56 | General |
| Category: PSYCHIATRY | ||||||
| 12/09/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $4,125.00 | General |
| 11/21/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $675.00 | General |
| 11/20/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,710.00 | General |
| Category: PSYCHIATRY | ||||||
| 11/13/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,700.00 | General |
| Category: PSYCHIATRY | ||||||
| 11/13/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Travel and Lodging | In-kind items and services | $891.95 | General |
| Category: PSYCHIATRY | ||||||
| 11/13/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Travel and Lodging | In-kind items and services | $324.66 | General |
| Category: PSYCHIATRY | ||||||
| 11/13/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $115.84 | General |
| Category: PSYCHIATRY | ||||||
| 11/13/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Travel and Lodging | Cash or cash equivalent | $81.40 | General |
| Category: PSYCHIATRY | ||||||
| 11/13/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | Cash or cash equivalent | $37.29 | General |
| Category: PSYCHIATRY | ||||||
| 10/30/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $79.33 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 10/24/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,560.00 | General |
| Category: PSYCHIATRY | ||||||
| 10/24/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: PSYCHIATRY | ||||||
| 10/24/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Travel and Lodging | Cash or cash equivalent | $103.84 | General |
| Category: PSYCHIATRY | ||||||
| 10/22/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $24.29 | General |
| Category: PSYCHIATRY | ||||||
| 10/21/2024 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $18.37 | General |
| Category: PSYCHIATRY | ||||||
| 10/10/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,560.00 | General |
| Category: PSYCHIATRY | ||||||
| 10/10/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $124.88 | General |
| Category: PSYCHIATRY | ||||||
| 10/10/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Travel and Lodging | Cash or cash equivalent | $105.50 | General |
| Category: PSYCHIATRY | ||||||
| 10/02/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,700.00 | General |
| Category: PSYCHIATRY | ||||||
| 10/02/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Travel and Lodging | In-kind items and services | $537.72 | General |
| Category: PSYCHIATRY | ||||||
| 10/02/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Travel and Lodging | Cash or cash equivalent | $337.33 | General |
| Category: PSYCHIATRY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 35 | 127 | $21,081 | $9,071 |
| 2022 | 3 | 66 | 319 | $63,863 | $22,894 |
| 2021 | 3 | 54 | 259 | $54,153 | $20,244 |
| 2020 | 3 | 59 | 333 | $60,615 | $22,039 |
Total Patients
214
Total Services
1,038
Medicare Billing
$74,248
Procedure Codes
11
All Medicare Procedures & Services
11 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 21 | 85 | $16,311 | $6,873 | 42.1% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2023 | 14 | 42 | $4,770 | $2,198 | 46.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 24 | 123 | $30,996 | $11,780 | 38.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 26 | 135 | $22,680 | $7,719 | 34.0% |
| 90833 | Psychotherapy with evaluation and management visit, 30 minutes | Office | 2022 | 16 | 61 | $10,187 | $3,395 | 33.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 26 | 131 | $33,012 | $12,982 | 39.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 17 | 95 | $15,630 | $5,386 | 34.5% |
| 90833 | Psychotherapy performed with evaluation and management visit, 30 minutes | Office | 2021 | 11 | 33 | $5,511 | $1,875 | 34.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 20 | 187 | $30,481 | $11,303 | 37.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 18 | 84 | $20,496 | $7,110 | 34.7% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 21 | 62 | $9,638 | $3,626 | 37.6% |
About Dr. Mark Zimmerman, MD
Dr. Mark Zimmerman, MD is a Psychiatry healthcare provider based in Cranston, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/19/2005. The National Provider Identifier (NPI) number assigned to this provider is 1508842857.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Zimmerman, MD has received a total of $218,647 in payments from pharmaceutical and medical device companies, with $67,776 received in 2024. These payments were reported across 166 transactions from 19 companies. The most common payment nature is "Consulting Fee" ($88,144).
As a Medicare-enrolled provider, Zimmerman has provided services to 214 Medicare beneficiaries, totaling 1,038 services with total Medicare billing of $74,248. Data is available for 4 years (2020–2023), covering 11 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Location Cranston, RI
- Active Since 12/19/2005
- Last Updated 10/07/2025
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1508842857
Products in Payments
- CAPLYTA (Drug) $54,725
- REXULTI (Drug) $27,783
- SPRAVATO (Drug) $9,288
- PRISTIQ (Drug) $4,500
- Cenobamate (Drug) $3,200
- VYVANSE (Drug) $111.66
- BOTOX (Biological) $79.33
- VRAYLAR (Drug) $50.71
- XYWAV (Drug) $50.15
- ARISTADA (Drug) $49.48
- INGREZZA (Drug) $28.21
- Auvelity (Drug) $20.53
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Cranston
Dr. Richard Miller, M.d, M.D
Psychiatry — Payments: $764,696
Psychiatry $764,696
Dr. Gene Jacobs, D.o, D.O
Psychiatry — Payments: $29,145
Psychiatry $29,145
Robert Bessette, D.o, D.O
Psychiatry — Payments: $13,613
Psychiatry $13,613
Dr. John Ruggiano, M.d, M.D
Psychiatry — Payments: $10,571
Psychiatry $10,571
Dr. Maria Gonzalez, Md, MD
Psychiatry — Payments: $4,575
Psychiatry $4,575
Dr. Bruce Fischer, Md, MD
Psychiatry — Payments: $193.28
Psychiatry $193.28